Development and In Vitro Evaluation of a Novel Pulsatile Drug Delivery System Containing Dexketoprofen Trometamol

Uğurlu, Timuçin; Ilhan, Ezgi

doi:10.1007/s12247-020-09452-2

Cited by 3 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given its biological half-life and physico-chemical characteristics, dexketoprofen is a good drug candidate for prolonged release, in order to improve patient compliance by reducing dose frequency. It has been formulated in prolonged released mini-matrix tablets [ 49 ], minitablets coated with Eudragit S and ethylcellulose for colon targeting [ 50 ], and gastroretentive systems by the wet granulation method with various grades of hydroxylpropyl methyl cellulose (HPMC) [ 51 ]. All these dosage forms have proved a modified release profile.…”

Section: Discussionmentioning

confidence: 99%

Biocompatibility and Pharmacological Effects of Innovative Systems for Prolonged Drug Release Containing Dexketoprofen in Rats

et al. 2021

View full text Add to dashboard Cite

The present study reports on the in vivo biocompatibility investigation and evaluation of the effects of liposomes containing dexketoprofen in somatic sensitivity in rats. Method: The liposomes were prepared by entrapping dexketoprofen in vesicular systems stabilized with chitosan. The in vivo biocompatibility was evaluated after oral administration in white Wistar rats: Group I (DW): distilled water 0.3 mL/100 g body weight; Group II (DEX): dexketoprofen 10 mg/kg body weight (kbw); Group III (nano-DEX): liposomes containing dexketoprofen 10 mg/kbw. Blood samples were collected from caudal lateral vein one day and seven days after the substance administration, to assess the eventual hematological, biochemical, and immunological changes. The investigation of somatic pain reactivity was performed using the hot plate test, to count the latency time response evoked by the thermal paws’ noxious stimulation. Results: Original liposomes entrapping dexketoprofen, with mean size of 680 nm and good stability, were designed. Laboratory analysis indicated no substantial variances between the three treated groups. The treatment with liposomes containing dexketoprofen resulted in a prolongation of the latency time response, statistically significant in the interval between 90 min and 10 h, in the hot plate test. Conclusions: The use of liposomes with dexketoprofen proved a good in vivo biocompatibility in rats and prolonged analgesic effects in the hot plate test.

show abstract

Section: Discussionmentioning

confidence: 99%

Biocompatibility and Pharmacological Effects of Innovative Systems for Prolonged Drug Release Containing Dexketoprofen in Rats

et al. 2021

View full text Add to dashboard Cite

show abstract

“…It was found that the combination of both Eudragit polymers in a (3:1) ratio enhanced the drug release rate by ∼ 95% within the first 6 h but did not achieve the colon target release due to premature drug release. Thus, findings concluded that the Eudragit S 100 and Surelease polymer combination has the potential to retard the drug release pattern and also maintain a deficient level for a more extended period [ 84 ].…”

Section: Classification Of Pulsatile Drug Deliverymentioning

confidence: 99%